Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Learn more about HealthTree

Video

What AML mutations benefit from targeted therapy?

Posted by

HealthTree

• August 24, 2022

Description

Learn which AML mutations benefit from targeted therapy in this video.

On this video

Eunice Wang, MD, Specialist

Roswell Park Cancer Institute

Transcript

What AML mutations benefit from targeted therapy? So currently targeted therapy for AML consists of a couple of drugs specific for mutations, FLIT3 inhibitors. We have one FLIT3 inhibitor approved Midastorin for upfront therapy and another one, GILT-RIT-Nib, approved for relapse and refractory disease. We have two inhibitors of IDH1 and IDH2 mutations which are Ivositinib and Anasitinib respectively.

Related Content